Meatable \Netherlands

Meatable was a Dutch cultivated meat (cellular agriculture) startup founded in 2018 that aimed to produce lab-grown pork and beef by harvesting pluripotent stem cells from animals and growing them in bioreactors. The 'why now' was compelling: rising global meat demand, climate concerns (livestock accounts for 14.5% of GHG emissions), and breakthroughs in stem cell biology made scalable cellular agriculture seem feasible. Meatable differentiated by claiming faster production cycles (weeks vs. months) using proprietary opti-ox technology for cell differentiation. They raised $100M from deep-tech investors like Agronomics and BlueYard, positioning themselves as a sustainability play that could deliver real meat without animal slaughter. The value proposition targeted both B2B (food manufacturers) and eventual B2C (premium meat alternatives), promising identical taste/texture to conventional meat while solving ethical and environmental problems. However, the gap between lab-scale proof-of-concept and commercial viability proved insurmountable within their capital runway.

SECTOR Consumer
PRODUCT TYPE Biotech
TOTAL CASH BURNED $100.0M
FOUNDING YEAR 2018
END YEAR 2025

Discover the reason behind the shutdown and the market before & today

Failure Analysis

Failure Analysis

Meatable's collapse was a textbook case of capital-intensive deeptech hitting the 'commercialization chasm' with insufficient runway. The mechanics: After raising $47M Series A (2021)...

Expand
Market Analysis

Market Analysis

The cultivated meat industry in 2025 is at an inflection point between hype cycle collapse and genuine technical progress. The 2018-2021 boom saw $3B+...

Expand
Startup Learnings

Startup Learnings

Wedge products beat moonshots in deeptech: Instead of whole-cut meat (highest complexity, longest regulatory path), modern founders should target B2B ingredients—cultivated fat for plant-based...

Expand
Market Potential

Market Potential

The global meat market is $1.4 trillion annually, with projected growth to $1.8T by 2030 driven by Asia-Pacific demand. The cultivated meat TAM is...

Expand
Difficulty

Difficulty

Cultivated meat remains at the absolute frontier of biotech complexity even in 2025. While AI tools (AlphaFold for protein engineering, ML-optimized bioreactor controls, GPT-4...

Expand
Scalability

Scalability

Cultivated meat has brutal unit economics that worsen with scale in the short term. Unlike software (zero marginal cost) or marketplaces (network effects), each...

Expand

Rebuild & monetization strategy: Resurrect the company

✓

Pivot Concept

+

An AI-first cultivated meat ingredient platform targeting B2B food manufacturers with three product lines: (1) cultivated animal fat for plant-based meat (improves mouthfeel/flavor), (2) precision-fermented growth factors sold to other cultivated meat startups (platform play), and (3) ultra-premium whole-cut Wagyu beef for Michelin-starred restaurants (halo product). The core differentiation is using generative AI and ML-optimized bioreactors to achieve 50% faster R&D cycles and 40% lower production costs than 2018-era competitors. Instead of vertically integrating into consumer brands (Meatable's mistake), CultivateLabs is a B2B infrastructure play—the 'TSMC of cultivated meat'—licensing cell lines, selling ingredients, and providing contract manufacturing. Revenue starts in Year 2 from growth factor sales, scales in Year 3-4 with cultivated fat for Beyond/Impossible-style hybrids, and the Wagyu product (launching Year 4) provides brand credibility and premium margin. This model requires $80M over 5 years vs. Meatable's $200M+ for consumer vertical integration, and generates cash flow 24 months earlier by targeting ingredient sales first.

Suggested Technologies

+
AlphaFold 3 for growth factor protein engineering and media optimizationGinkgo Bioworks Foundry partnership for cell line development and strain engineeringML-optimized bioreactor control systems (real-time monitoring, predictive maintenance)Benchling for R&D data management and regulatory documentationStripe for B2B invoicing and subscription billing (growth factor customers)Supabase for customer portal and order managementClaude/GPT-4 for automated regulatory filing generation (GRAS petitions, Novel Foods dossiers)Retool for internal ops dashboards (production tracking, QC)Continuous bioreactor systems (perfusion culture) vs. batch processing for 3x productivityComputational fluid dynamics (CFD) modeling for bioreactor design optimizationAutomated liquid handling robotics for high-throughput media screening
•

Execution Plan

+

Phase 1

+

Wedge (Months 1-18, $8M): Partner with Ginkgo Bioworks to develop 3 proprietary cell lines (bovine fat, porcine fat, bovine muscle) optimized for serum-free media. Use AlphaFold + ML to design growth factor cocktails that reduce media costs from $400/L to $80/L. Simultaneously, develop precision fermentation process for producing FGF2 and TGF-β growth factors. Secure Singapore regulatory pre-approval pathway. Deliver first 10kg of cultivated fat to 2 plant-based meat companies (Beyond, Impossible) for R&D trials. Validate that 5-10% cultivated fat inclusion improves sensory scores by 30%+. Revenue: $0, but secure 2 LOIs (letters of intent) for Year 2 ingredient purchases.

Phase 2

+

Validation (Months 19-36, $20M): Build 500L pilot bioreactor facility in Singapore. Achieve $50/lb cost for cultivated fat at 500kg/month production. Launch B2B growth factor sales to 5 cultivated meat startups at $2,000/gram (80% margin). Secure offtake agreements with 3 food manufacturers for cultivated fat (hybrid burger/sausage applications) at $30/lb, totaling $2M annual revenue. File GRAS petition with FDA for cultivated bovine fat. Initiate Wagyu whole-cut R&D using 3D bioprinting + edible scaffolding. Hire regulatory team to navigate EU Novel Foods process. Revenue: $3M Year 2 (growth factors + pilot fat sales), burn $12M, raise Series A ($25M) at $80M valuation.

Phase 3

+

Growth (Months 37-54, $35M): Build 5,000L commercial bioreactor facility (Singapore + US). Scale cultivated fat production to 50 tons/year, hitting $15/lb cost. Sign contracts with 8 food manufacturers supplying hybrid products to Whole Foods, Kroger. Launch precision fermentation facility producing 100kg/year of growth factors, capturing 30% of the cultivated meat ingredient market. Receive FDA GRAS approval for fat; begin US sales. Debut Wagyu whole-cut steaks at 3 Michelin restaurants in Singapore/SF at $200/lb (limited production, 500kg/year). This creates brand halo and media coverage. Revenue: $18M Year 3 (60% ingredients, 30% fat, 10% Wagyu), $35M Year 4. Raise Series B ($50M) at $300M valuation to fund EU expansion.

Phase 4

+

Moat (Months 55+, $17M): Establish IP moat with 15+ patents on cell lines, media formulations, and bioprocess optimization. Build data flywheel—each production batch improves ML models for yield/cost optimization, creating 18-month lead over competitors. Expand to EU market post-Novel Foods approval. Launch contract manufacturing service (CMO model) where other cultivated meat startups pay to use CultivateLabs' bioreactors, creating asset utilization revenue. Develop second-generation Wagyu using gene-edited cells (CRISPR-enhanced marbling) for $120/lb cost, targeting Japan market. Revenue: $60M Year 5, $140M Year 6. Path to profitability in Year 6 with 35% gross margins. Exit options: (1) acquisition by ADM/Cargill/Tyson as their cultivated meat division, (2) IPO as infrastructure play (comp: Ginkgo Bioworks), or (3) continue as independent platform capturing 20% of $10B cultivated ingredient market by 2032.

•

Monetization Strategy

+
Three revenue streams with different margin profiles and timelines: (1) Precision-fermented growth factors (Year 2+): Sell FGF2, TGF-β, and albumin to 20+ cultivated meat startups at $1,500-3,000/gram. Customers include UPSIDE, Aleph Farms, Mosa Meat who currently pay $5,000/gram from Sigma-Aldrich. Target $8M revenue by Year 4 at 75% gross margin (fermentation scales well). This is the early cash flow engine. (2) Cultivated fat ingredients (Year 3+): B2B sales to plant-based meat manufacturers at $20-30/lb (vs. $50/lb for whole cuts). Customers blend 5-10% into hybrid products, improving taste while keeping retail price competitive. Contract structure: 3-year offtake agreements with minimum purchase commitments (500kg-5 tons/year per customer). Target $40M revenue by Year 5 at 45% gross margin. This is the scale business. (3) Ultra-premium Wagyu whole cuts (Year 4+): Limited production (2-5 tons/year) sold to Michelin restaurants and luxury retailers at $150-200/lb. This is a loss leader initially (30% margin) but creates brand value and proves technical capability for eventual mass-market whole cuts in 2030s. Target $8M revenue by Year 6. Additionally, Year 5+ contract manufacturing (CMO) revenue: charge other startups $500/L bioreactor time + 20% margin on consumables, generating $12M+ annually while improving asset utilization from 60% to 85%. Total Year 6 revenue projection: $140M (30% growth factors, 50% fat ingredients, 10% Wagyu, 10% CMO) with blended 48% gross margin and path to 15% EBITDA margin by Year 7. The model works because it generates cash 24 months earlier than consumer brands, diversifies revenue across B2B segments, and builds a moat through proprietary cell lines + ML-optimized processes that compress costs 40% below 2018-era competitors.

Related Startup Failures

BIOTECH
Views 30

Fermata

\Israel
🔥 $5.0M

THE VALUE PROPOSITION

Precision fermentation tech producing sustainable, animal-free proteins to replace dairy and meat ingredients with lower environmental impact.

CAUSE OF DEATH

Failed to achieve commercial-scale production economics; burned through capital before reaching cost parity with traditional proteins.

🚀
Rise
2019
🪦
Fall
2024
Market potential
Scale potential
Rebuild potential
💀
RAN OUT OF CASH
BIOTECH
Views 23

Spotlight Bio

\USA
🔥 $40.0M

THE VALUE PROPOSITION

AI-powered platform to identify and validate novel drug targets using genomics and computational biology, aiming to reduce pharma R&D failure rates.

CAUSE OF DEATH

Failed to bridge the gap between computational predictions and wet-lab validation; long timelines and capital intensity exceeded runway.

🚀
Rise
2018
🪦
Fall
2025
Market potential
Scale potential
Rebuild potential
💀
PRODUCT/TECH FAILURE
BIOTECH
Views 52

Sichuan Kelun-Biotech

\China
🔥 $400.0M

THE VALUE PROPOSITION

Chinese ADC biotech aiming to develop next-gen cancer therapies leveraging lower costs and faster trials to compete globally.

CAUSE OF DEATH

Burned $400M without approvals in overcrowded ADC market; clinical failures and regulatory delays killed runway.

🚀
Rise
2016
🪦
Fall
2024
Market potential
Scale potential
Rebuild potential
💀
RAN OUT OF CASH
GET BACK TO START-UP GRAVEYARD

Disclaimer: This entry is an AI-assisted summary and analysis derived from publicly available sources only (news, founder statements, funding data, etc.). It represents patterns, opinions, and interpretations for educational purposes—not verified facts, accusations, or professional advice. AI can contain errors or ‘hallucinations’; all content is human-reviewed but provided ‘as is’ with no warranties of accuracy, completeness, or reliability. We disclaim all liability for reliance on or use of this information. If you are a representative of this company and believe any information is inaccurate or wish to request a correction, please click the Disclaimer button to submit a request.